GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 275 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 275 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $78.48, for a total value of $21,582.00. Following the sale, the chief financial officer now directly owns 2,950 shares in the company, valued at approximately $231,516. This represents a 8.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The shares were sold at an average price of $93.82, for a total transaction of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total transaction of $108,737.20.
• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The shares were sold at an average price of $76.75, for a total transaction of $286,124.00.
• On Monday, December 9th, Kevin Feeley sold 1,137 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total transaction of $86,832.69.
• On Monday, December 2nd, Kevin Feeley sold 263 shares of GeneDx stock. The shares were sold at an average price of $78.39, for a total value of $20,616.57.
• On Thursday, November 21st, Kevin Feeley sold 12,019 shares of GeneDx stock. The stock was sold at an average price of $73.76, for a total value of $886,521.44.

GeneDx Stock Down 3.9 %

WGS stock opened at $74.85 on Friday. The firm’s 50-day moving average is $78.29 and its two-hundred day moving average is $57.97. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of -24.07 and a beta of 2.02. GeneDx Holdings Corp. has a 52 week low of $3.62 and a 52 week high of $98.87.

GeneDx (NASDAQ:WGS) last released its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The firm had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. During the same period in the prior year, the firm posted ($0.82) earnings per share. The firm’s revenue for the quarter was up 44.3% compared to the same quarter last year. On average, analysts forecast that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Institutional Trading of GeneDx

Several institutional investors have recently modified their holdings of WGS. MCF Advisors LLC boosted its holdings in GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company’s stock worth $27,000 after buying an additional 182 shares in the last quarter. Global Retirement Partners LLC bought a new stake in shares of GeneDx during the 4th quarter worth $28,000. Rhumbline Advisers grew its holdings in shares of GeneDx by 5.5% in the 4th quarter. Rhumbline Advisers now owns 19,750 shares of the company’s stock worth $1,518,000 after acquiring an additional 1,021 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of GeneDx by 10.6% during the fourth quarter. Principal Financial Group Inc. now owns 15,751 shares of the company’s stock worth $1,211,000 after purchasing an additional 1,511 shares during the period. Finally, Palumbo Wealth Management LLC lifted its holdings in shares of GeneDx by 22.8% during the fourth quarter. Palumbo Wealth Management LLC now owns 8,303 shares of the company’s stock valued at $638,000 after purchasing an additional 1,542 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on WGS. TD Cowen increased their target price on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. Craig Hallum lifted their price objective on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Wells Fargo & Company upped their target price on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Finally, The Goldman Sachs Group boosted their price objective on GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, GeneDx has an average rating of “Moderate Buy” and a consensus price target of $70.67.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.